Company | Ticker | Business Description | Underwriters | Offer Date |
---|---|---|---|---|
Hangzhou SF Intra-city> | |
|||
Impel NeuroPharma> | IMPL> | Late-stage developer of intranasal drug formulations for migraines and CNS diseases. | TD Cowen Guggenheim Sec. |
04/22/21 |
Intensity Therapeutics> | INTS> | Phase 2 biotech developing intratumoral injection therapies for cancer. | The Benchmark Compan Freedom Cap.Mkts |
06/29/23 |
Intrepid Acquisition I> | IACIU> | Blank check company formed by Intrepid Potash targeting energy, natural resources, and infrastructure. | TD Cowen Intrepid Partners |
Withdrawn |
Intrinsic Medicine> | INRX> | Preclinical biotech developing synthetic human milk to treat gut and inflammatory disorders. | Spartan Capital Sec. Revere Sec. |
Withdrawn |
Intrusion> | INTZ> | Provides a family of software products for enterprise security. | B. Riley Sec. |
10/08/20 |
NeOnc Technologies> | NTHI> | Phase 2 biotech developing intranasal and oral therapies for brain cancer. | Loop Cap.Mkts Maxim |
Apr 2024 |
RxSight> | RXST> | Sells premium adjustable intraocular lenses used in cataract surgery. | JP Morgan BofA Sec. |
07/29/21 |
News Results for INTR |
---|